Stopping and Restarting GLP-1 Is Normal — Here's What Holds the Loss

If you've stopped a GLP-1 medication and then started again — or you're sitting in a gap right now, refill unfilled, wondering what it means about you — read this first: you are not the exception. You're the pattern. And a pause in the medication is not a verdict on your journey.

New data presented this week makes that plain. The story of these drugs in real life is far less of a straight line than the headlines suggested, and far more human.

TL;DR: New ENDO 2026 data shows GLP-1 use is more "start-and-stop" than assumed — about 4 in 10 people stopped within a year, and most who stopped later restarted. Stopping isn't failure. What protects your loss through a pause is the behavior layer: the habits you keep when the medication isn't doing the work for you.

The start-and-stop reality

At the Endocrine Society's ENDO 2026 meeting in Chicago, researchers led by Sainikhil Sontha of Boston University School of Public Health looked at more than 60,000 adults with type 2 diabetes on liraglutide, semaglutide, or tirzepatide, using six and a half years of U.S. claims data. They counted a refill gap of more than 60 days as "stopping," and a new fill after that gap as restarting.

What they found reframes the whole conversation. About 4 in 10 people stopped within the first year, and nearly 6 in 10 had stopped by the end of two years. As Sontha put it, "use is more start-and-stop than most people assumed." (Endocrine Society, ENDO 2026)

Notice the shape of that. The bigger cliff isn't year one — it's the second year. That's the part of the journey where the early novelty has worn off, the appetite-quiet feels routine, and life (cost, coverage, side effects, a move, a job change) starts pulling at consistency.

And here's a piece of context worth holding alongside it: staying on isn't getting harder — it's getting easier. A 2026 analysis in the Journal of Managed Care & Specialty Pharmacy found one-year persistence on semaglutide (Wegovy) rose steadily as supply and coverage stabilized — from 33.2% in 2021 to 58.6% by the first half of 2024. (JMCP, 2026) More people are holding the line than a few years ago. The cliff is real, but it's not fixed.

Why people stop — and it's rarely about wanting to

The ENDO 2026 data is honest about who stops and why. People dealing with nausea or other GI side effects were more likely to discontinue within a year (about 37%). So were patients on Medicaid or Medicare, and Black patients — a signal that cost and access, not motivation, do a lot of the deciding.

A few other threads stand out. People whose first GLP-1 was prescribed by an endocrinologist were 10% less likely to stop. Tirzepatide users were 41% less likely to discontinue than liraglutide users, and semaglutide users 28% less likely — differences that likely track with tolerability and how the medication feels day to day.

The takeaway isn't that some people have "willpower" — it's that stopping is usually a response to real friction. Side effects, a bill, a pharmacy gap. If any of that is shaping your decision, that's a conversation for your prescriber, not a self-judgment.

Restarting is common — but consistency matters

Here's the hopeful half of the same study: most people who stopped came back. Of those who discontinued, 41.5% restarted within a year, and 58% within two. The gap, for many, is a chapter — not the end.

But the restart comes with a nuance worth respecting. A separate study in JCI Insight found that inconsistent use may reduce how well the medication works when you resume — the authors wrote that "the effectiveness of these medications may depend heavily on consistency." (NewsNation) No new safety concerns surfaced. But it's a reminder that a stop-start rhythm isn't free, and that anything about pausing or restarting belongs in a conversation with your clinician.

What actually holds the loss: the behavior layer

This is where the medication story and your story diverge — in the most encouraging way.

The often-quoted modeled figure is that roughly 60% of weight lost is regained a year after stopping. (ScienceDirect) That number describes the medication coming out of the system. It does not describe you.

Because the real-world picture is different. A 2026 Cleveland Clinic analysis of nearly 8,000 patients who stopped semaglutide or tirzepatide found that, on average, people did not see dramatic regain: the group treated for obesity had lost about 8.4% of their body weight and regained only around 0.5% a year later, and 45% kept losing or stayed the same. (Cleveland Clinic) Sit with that. The difference wasn't luck — most people did something next: 27% switched to another treatment, 20% restarted their original medication, and 14% kept going with lifestyle support from a dietitian or exercise specialist. That's the behavior layer: the habits and support that keep working when the medication pauses.

That's the whole reframe. The window the medication opens — quieter appetite, more room to choose — is when habits get built. And habits, unlike a prescription, don't lapse after a 60-day gap. They're what you keep when you stop. As Sontha said, "consistent use of these medications is what produces their protective effects" — and the behaviors you build inside that consistency are what protect the loss when use isn't perfect.

What to do with this

You don't have to promise yourself you'll never stop. That's not the goal, and for a lot of people it's not realistic. The goal is to use the window — however long it lasts this stage — to build habits that outlast the prescription, so a pause becomes a chapter and not a reset. If your medication has stopped feeling like it's working the way it did, that's worth understanding too — here's what can change. And if you're wondering where your own habits stand right now, the habit readiness assessment is a quiet place to start.

This isn't about never stopping. It's about what you keep when you do.

Key Takeaways

Treat a pause as a chapter, not a verdict. Stopping and restarting is the common reality, not a personal failing — most people who stop come back to it.
Use the medication window to build, not just to lose. The quieter appetite is your opening to lay down habits that keep working through a gap.
Anchor your loss to behavior, not only the dose. Real-world data shows average regain after stopping is small when people restart, switch, or add lifestyle support — that's the part that's yours to keep.
If friction is pushing you toward stopping, name it to your prescriber. Side effects, cost, and access drive most stopping — those have a clinical path, not a willpower one.
Aim for a steadier rhythm over a perfect one. Consistency improves how the medication works, so lean toward fewer, shorter gaps — and talk to your clinician about timing.

A quiet next step

If this reframe lands, two ways to keep going. Our newsletter sends one honest, research-grounded read a week — the kind of context the headlines skip. And if you want a place to build the habits that hold the loss through a pause, that's what we're piloting now — habits designed to survive a gap in the medication, not depend on it.

This article covers research on GLP-1 persistence. It is not medical advice. For questions about your own medication, talk to your prescriber.

Frequently asked questions

Is it bad to stop and restart a GLP-1? Stopping and restarting is common — the ENDO 2026 data shows most people who stop later restart. The main caution from a separate JCI Insight study is that inconsistent use may reduce how well the medication works when you resume; no new safety issues were found. Anything about pausing or restarting should go through your prescriber.

Will I regain all the weight if I stop? A modeled figure suggests roughly 60% of lost weight is regained a year after stopping. But real-world data is more reassuring: a 2026 Cleveland Clinic analysis of nearly 8,000 patients found average regain a year after stopping was small — the obesity group regained only about 0.5% — largely because people restarted, switched, or added lifestyle support (Cleveland Clinic).

Why do so many people stop in the first year? Often it's friction, not motivation — GI side effects, cost, and access were the strongest signals in the ENDO 2026 data. People prescribed by an endocrinologist were 10% less likely to stop, which points to support and follow-up mattering.

Are fewer people quitting than a couple of years ago? Yes. One-year persistence on semaglutide rose from 33.2% in 2021 to 58.6% by the first half of 2024 as supply and coverage stabilized, per a 2026 JMCP analysis. Staying on has been getting easier, not harder.